摘要
目的:通过测量转化生长因子(TGF-β)和表皮生长因子受体(EGFR)的血清浓度,探讨其对肝癌(HCC)的检测敏感度。方法:共67例肝病患者,其中肝癌41例、肝转移癌15例、肝硬化11例;30例健康体检者为对照组。用酶联免疫法测量所有研究对象的血清TGF-β和EGFR浓度。结果:肝病患者的TGF-β和EGFR平均浓度明显高于对照组(P<0.01)。肝癌患者的TGF-β和EGFR浓度明显高于肝转移癌和肝硬化患者。结论:TGF-β和EGFR检测HCC具有可信性。
Objective ： To improve the detection of HCC by measuring the serum concentration of transforming growth factor beta （TGF-β ） and epidermal growth factor receptor（EGFR）.Methods ： Sixty-seven patients with liver disease, 41 with hepatocellular carcinoma, 15 with liver metastasis, 11 with liver cirrhosis and 30 healthy volunteers were evaluated.TGF- β and EGFR were detected with enzyme-linked immunoassay （ELISA） in serum of all study participants. Results ： The mean values of TGF- β and EGFR in all patients were much higher than in control group（P〈0.01）.In HCC patients the levels of TGF- βand EGFR were much higher than in liver metastasis and liver cirrhosis patients.Conclusion ： It is reliability for TGF- β and EGFR in detecting HCC.
出处
《中外医学研究》
2012年第33期35-36,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
常州市卫生局科技项目(项目编号:ZD201005)
常州市科技支撑-社会发展项目(项目编号:CE20125026)
关键词
肝癌
转化生长因子
表皮生长因子受体
Hepatocellular carcinoma
Transforming growth factor beta
Epidermal growth factor receptor
